DTaP-IPV/Hib vaccine

DTaP-IPV/Hib vaccine
Combination of
DTaP vaccineVaccine
Inactivated poliovirus vaccineVaccine
Hib vaccineVaccine
Clinical data
Trade namesPentacel, Pediacel, Infanrix IPV + Hib, others
AHFS/Drugs.comFDA Professional Drug Information
Routes of
administration		Intramuscular injection
ATC code
Legal status
Legal status
Identifiers
CAS Number

DTaP-IPV/Hib vaccine is a 5-in-1 combination vaccine that protects against diphtheria, tetanus, whooping cough, polio, and Haemophilus influenzae type B.

Its generic name is "diphtheria and tetanus toxoids and acellular pertussis adsorbed, inactivated poliovirus and haemophilus B conjugate vaccine", and it is also known as DTaP-IPV-Hib.

Uses

DTaP-IPV/Hib vaccine is administered to young children to immunise against diphtheria, tetanus, pertussis, poliomyelitis, and diseases caused by Haemophilus influenzae type B.

Formulations

A branded formulation marketed in the United States is Pentacel, manufactured by Sanofi Pasteur.

Pentacel is known in the UK and Canada as Pediacel. In April 2024, Sanofi discontinued Pediacel in Canada, transitioning to Pentacel.

An equivalent vaccine marketed in the UK and Canada by GlaxoSmithKline is Infanrix IPV + Hib. This is a two-part vaccine. The DTaP-IPV component is supplied as a sterile liquid, which is used to reconstitute lyophilized (freeze-dried) Hib vaccine.[citation needed]

Pentaxim is a liquid formulation marketed by Sanofi Pasteur.

Availability

It is only licensed for young children. The United States Food and Drug Administration has approved[when?] the vaccine for children from age 6 weeks up to age 5 years. It was used in the UK until 2017, following which a 6-in-1 vaccine became available containing the additional protection against Hepatitis B.

References

  1. 1 2 3 4 "Diphtheria and Tetanus Toxoids, Acellular Pertussis, Poliovirus and Haemophilus b Conjugate Vaccine". Drugs.com. Retrieved 15 July 2018.
  2. 1 2 "5-in-1 Vaccine (also called Pentavalent Vaccine)". Vaccine Knowledge Project. 3 January 2021. Retrieved 3 July 2018.
  3. ↑ "Pentacel". U.S. Food and Drug Administration(FDA). STN 125145. Archived from the original on 27 August 2009. Retrieved 15 July 2018.
  4. ↑ "Pediacel syringe - Summary of Product Characteristics (SmPC)". Datapharm. 17 April 2019. Archived from the original on 17 October 2019. Retrieved 16 October 2019.
  5. 1 2 "Diphteria Toxoid: Canadian Immunization Guide". Public Health Agency of Canada. December 2014. Archived from the original on 24 September 2019. Retrieved 16 October 2019.
  6. ↑ "Transition to Boostrix® & Pentacel® Vaccines" (PDF). Durham Region Health Department. 20 March 2024. Archived (PDF) from the original on 26 February 2026. Retrieved 3 June 2026.
  7. ↑ "Tetanus toxoid: Canadian Immunization Guide". Public Health Agency of Canada. 3 June 2026. Retrieved 3 June 2026.{{cite web}}: CS1 maint: url-status (link)
  8. ↑ Plotkin SA, Liese J, Madhi SA, Ortiz E (July 2011). "A DTaP-IPV/PRP~T vaccine (Pentaxim): a review of 16 years' clinical experience". Expert Rev Vaccines. 10 (7): 981–1005. doi:10.1586/erv.11.72. PMID 21749196. S2CID 207224675.
  9. ↑ "Diphtheria toxoid / haemophilus b conjugate (prp-t) vaccine / pertussis, acellular / poliovirus vaccine, inactivated / tetanus toxoid (Pentacel) Use During Pregnancy". Drugs.com. Retrieved 2 January 2021.